Meta-analysis on the efficacy and safety of moxifloxacin and levofloxacin in the treatment of urinary tract infections

LIU Xu; CAI Yun; ZHU Ya-ping; LI Jiao

Abstract：Objective: To evaluate the efficacy and safety of moxifloxacin as well as levofloxacin in the treatment of urinary tract infections, and provide evidence for clinical therapy in China. Methods:We searched the data base in China to collect all the original studies with the key words as moxilfoxacin, levolfoxacin, urinary tract infection. Data were analyzed by Rev Man 5.1 software. Results:A total of 12 randomized controlled trials involving 1110 patients were included. The values of combined OR for efifcacy, clinical cure rate, incidence of adverse reaction and bacterial eradication rate were 1.81 (P=0.01), 1.67 (P=0.002), 0.75 (P=0.21), 1.70 (P=0.10) respectively. Meta-analysis showed that moxilfoxacin was more effective than levolfoxacin in the treatment of urinary tract infections. However, there was no statistical difference in incidence of adverse reaction and bacterial eradication rate. Subgroup analysis of oral and intravenous administration indicated that oral moxilfoxacin was better than levolfoxacin in efifcacy and clinical cure rate in the treatment of urinary tract infections, while intravenous moxilfoxacin showed no statistical difference compared with levolfoxacin. Conclusion:Moxilfoxacin was an effective and safe antibacterial agent in the treatment of urinary tract infections, and the result should be authenticated in the future with many samples, high quality study, detail method description, etc.